Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil.

Citation data:

Journal of inorganic biochemistry, ISSN: 1873-3344, Vol: 117, Page: 85-92

Publication Year:
2012
Usage 582
Abstract Views 523
Link-outs 59
Captures 59
Readers 32
Exports-Saves 27
Mentions 10
News Mentions 9
Blog Mentions 1
Social Media 244
Shares, Likes & Comments 165
Tweets 79
Citations 22
Citation Indexes 22
PMID:
23078778
DOI:
10.1016/j.jinorgbio.2012.08.015
Author(s):
Lee, Sin Hang
Publisher(s):
Elsevier BV
Tags:
Biochemistry, Genetics and Molecular Biology, Chemistry
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
Medical practitioners in nine countries submitted samples of Gardasil (Merck & Co.) to be tested for the presence of human papillomavirus (HPV) DNA because they suspected that residual recombinant HPV DNA left in the vaccine might have been a contributing factor leading to some of the unexplained post-vaccination side effects. A total of 16 packages of Gardasil were received from Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain and the United States. A nested polymerase chain reaction (PCR) method using the MY09/MY11 degenerate primers for initial amplification and the GP5/GP6-based nested PCR primers for the second amplification were used to prepare the template for direct automated cycle DNA sequencing of a hypervariable segment of the HPV L1 gene which is used for manufacturing of the HPV L1 capsid protein by a DNA recombinant technology in vaccine production. Detection of HPV DNA and HPV genotyping of all positive samples were finally validated by BLAST (Basic Local Alignment Search Tool) analysis of a 45-60 bases sequence of the computer-generated electropherogram. The results showed that all 16 Gardasil samples, each with a different lot number, contained fragments of HPV-11 DNA, or HPV-18 DNA, or a DNA fragment mixture from both genotypes. The detected HPV DNA was found to be firmly bound to the insoluble, proteinase-resistant fraction, presumably of amorphous aluminum hydroxyphosphate sulfate (AAHS) nanoparticles used as adjuvant. The clinical significance of these residual HPV DNA fragments bound to a particulate mineral-based adjuvant is uncertain after intramuscular injection, and requires further investigation for vaccination safety.

This article has 0 Wikipedia mention.